Checkpoint Immunotherapy Targets CDK12-Mutant Metastatic Cancers in Phase 2 Trial
A completed Phase 2 trial tests nivolumab plus ipilimumab in CDK12-mutant metastatic prostate and solid tumors across 56 patients.
Summary
CDK12 is a gene that, when mutated, disrupts DNA repair in cancer cells — potentially making tumors more visible to the immune system. This Phase 2 trial at the University of Michigan enrolled 56 patients with metastatic castration-resistant prostate cancer and other solid tumors harboring CDK12 loss-of-function mutations. Patients received either the combination immunotherapy nivolumab plus ipilimumab followed by nivolumab alone, or nivolumab monotherapy. The study aimed to determine whether CDK12 mutations could serve as a biomarker to identify prostate cancer patients who might respond to checkpoint inhibitors — a class of drugs that has largely underperformed in prostate cancer. Results from this completed trial could help oncologists better select patients most likely to benefit from immunotherapy.
Detailed Summary
Prostate cancer has historically been resistant to immune checkpoint inhibitors, which have revolutionized treatment in cancers like melanoma and lung cancer. Identifying genomic subsets of prostate cancer that may respond to immunotherapy is a critical research priority, and CDK12 mutations have emerged as a promising candidate biomarker.
CDK12 encodes a kinase involved in DNA damage repair. When CDK12 is lost or mutated, cancer cells accumulate genomic instability — specifically focal tandem duplications — that may generate neoantigens and increase tumor immunogenicity. This makes CDK12-mutant tumors plausible candidates for immune checkpoint blockade.
This Phase 2 trial, sponsored by the University of Michigan Rogel Cancer Center, enrolled 56 patients with metastatic cancers — primarily castration-resistant prostate cancer — harboring CDK12 loss-of-function mutations. Participants received either nivolumab (anti-PD-1) combined with ipilimumab (anti-CTLA-4) followed by nivolumab maintenance, or nivolumab monotherapy. The dual-arm design allowed comparison of combination versus single-agent immunotherapy in this biomarker-selected population.
The trial completed in March 2024 after more than five years of enrollment and follow-up. Full efficacy and safety results have not yet been published in the abstract provided, but the completion of this study represents a meaningful contribution to the question of whether CDK12 mutation status can guide immunotherapy selection in prostate cancer — a disease where actionable genomic-immune correlations remain scarce.
If positive results emerge, this trial could help establish CDK12 as a companion diagnostic biomarker for checkpoint inhibitor use in prostate cancer, fundamentally shifting how a subset of patients with this difficult-to-treat disease are managed. Caveats include the relatively small sample size and the need to await full peer-reviewed publication of outcomes.
Key Findings
- CDK12 loss-of-function mutations were used as the primary biomarker to select patients for checkpoint immunotherapy.
- Combination nivolumab plus ipilimumab was tested against nivolumab monotherapy in metastatic prostate cancer.
- The trial enrolled 56 patients across metastatic castration-resistant prostate cancer and other solid tumors.
- Trial completed in March 2024, with full results pending formal publication.
- CDK12 mutation may represent a rare actionable immune biomarker in otherwise immunotherapy-resistant prostate cancer.
Methodology
Phase 2, single-institution trial at the University of Michigan enrolling 56 patients with CDK12 loss-of-function metastatic cancers. Two arms were studied: nivolumab plus ipilimumab combination followed by nivolumab monotherapy, versus nivolumab monotherapy alone. Trial ran from December 2018 to March 2024.
Study Limitations
Summary is based on the abstract and ClinicalTrials.gov registration only, as the full study results have not been published in peer-reviewed form. The 56-patient sample size is small, limiting statistical power for definitive efficacy conclusions. Single-institution design may limit generalizability across broader prostate cancer patient populations.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.